Merit Medical Systems Inc. is set to acquire Becton, Dickinson and Co.'s (BD) soft tissue core needle biopsy offerings and C.R. Bard Inc.'s drainage products for $100 million in a deal set to close at the end of this year. The assets are being sold in conjunction with Franklin Lakes, N.J.-based BD proposed acquisition of Murray Hill, N.J.-based C.R. Bard for $24 billion. The merger was first reported in April.